Literature DB >> 10870062

Identification and characterization of circulating prostate carcinoma cells.

Z P Wang1, M A Eisenberger, M A Carducci, A W Partin, H I Scher, P O Ts'o.   

Abstract

BACKGROUND: Analysis of prostate carcinoma cells isolated from the peripheral blood suggested a classification based on three categories.
METHODS: Centrifugation density gradients and magnetic cell sorting were used to isolate circulating prostate carcinoma cells from peripheral blood. Immunocytochemistry staining and fluorescent in situ hybridization allowed characterization of isolated cancer cells.
RESULTS: Terminal cells can be divided into 3 classes: 1) large, buoyant, fragile cells with a large nucleus that were captured in a 1.068 g/mL gradient; 2) enucleate cells (4, 6-diamidino-2-phenylindole [DAPI] negative) that were positive for cytokeratin and PSMA antibodies; and 3) cellular debris exhibiting cytokeratin and PSMA positive staining as well as nuclear debris identified by DAPI staining, which included cytoplasmic debris. Growing cells also exhibited three morphologic characteristics: those possessing stem cell-like morphology and characteristics such as small size, high density, developed cytokeratin systems, PSMA expression, and aneuploidy; those in M phase; and cell clusters. The majority of isolated cells exhibited intermediate characteristics and thus comprised the third group of circulating cancer cells.
CONCLUSIONS: Although the significance of the cluster remains undetermined, observation suggests that the cluster has the ability to circulate as a microtumor and subsequently arrest in the small veins and capillaries. It is hypothesized that the clusters could escape certain facets of immune surveillance and possibly gain a selective growth advantage over single cells in a distant site. Further hypothesis proposes that arrested cells recruit growth-promoting nutrients, which would result in the invasion of local blood vessels and vascularization. Copyright 2000 American Cancer Society.

Entities:  

Mesh:

Year:  2000        PMID: 10870062     DOI: 10.1002/1097-0142(20000615)88:12<2787::aid-cncr18>3.0.co;2-2

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  25 in total

Review 1.  New trial designs to assess antitumor and antiproliferative agents in prostate cancer.

Authors:  Walter Stadler
Journal:  Invest New Drugs       Date:  2002-05       Impact factor: 3.850

2.  Separation of tumor cells with dielectrophoresis-based microfluidic chip.

Authors:  Mohammed Alshareef; Nicholas Metrakos; Eva Juarez Perez; Fadi Azer; Fang Yang; Xiaoming Yang; Guiren Wang
Journal:  Biomicrofluidics       Date:  2013-01-09       Impact factor: 2.800

Review 3.  Molecular analysis of circulating tumour cells-biology and biomarkers.

Authors:  Matthew G Krebs; Robert L Metcalf; Louise Carter; Ged Brady; Fiona H Blackhall; Caroline Dive
Journal:  Nat Rev Clin Oncol       Date:  2014-01-21       Impact factor: 66.675

4.  Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer.

Authors:  Shannon L Stott; Richard J Lee; Sunitha Nagrath; Min Yu; David T Miyamoto; Lindsey Ulkus; Elizabeth J Inserra; Matthew Ulman; Simeon Springer; Zev Nakamura; Alessandra L Moore; Dina I Tsukrov; Maria E Kempner; Douglas M Dahl; Chin-Lee Wu; A John Iafrate; Matthew R Smith; Ronald G Tompkins; Lecia V Sequist; Mehmet Toner; Daniel A Haber; Shyamala Maheswaran
Journal:  Sci Transl Med       Date:  2010-03-31       Impact factor: 17.956

Review 5.  Circulating tumors cells as biomarkers: progress toward biomarker qualification.

Authors:  Daniel C Danila; Klaus Pantel; Martin Fleisher; Howard I Scher
Journal:  Cancer J       Date:  2011 Nov-Dec       Impact factor: 3.360

6.  Isolation of circulating tumor cells using a microvortex-generating herringbone-chip.

Authors:  Shannon L Stott; Chia-Hsien Hsu; Dina I Tsukrov; Min Yu; David T Miyamoto; Belinda A Waltman; S Michael Rothenberg; Ajay M Shah; Malgorzata E Smas; George K Korir; Frederick P Floyd; Anna J Gilman; Jenna B Lord; Daniel Winokur; Simeon Springer; Daniel Irimia; Sunitha Nagrath; Lecia V Sequist; Richard J Lee; Kurt J Isselbacher; Shyamala Maheswaran; Daniel A Haber; Mehmet Toner
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-07       Impact factor: 11.205

Review 7.  Detection and isolation of circulating tumor cells in urologic cancers: a review.

Authors:  Robert D Loberg; Yaron Fridman; Brian A Pienta; Evan T Keller; Laurie K McCauley; Russell S Taichman; Kenneth J Pienta
Journal:  Neoplasia       Date:  2004 Jul-Aug       Impact factor: 5.715

8.  Identification of prostate cancer mRNA markers by averaged differential expression and their detection in biopsies, blood, and urine.

Authors:  V Uma Bai; Ahmed Kaseb; Sheela Tejwani; George W Divine; Evelyn R Barrack; Mani Menon; Arthur B Pardee; G Prem-Veer Reddy
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-05       Impact factor: 11.205

Review 9.  Nanotheranostics of circulating tumor cells, infections and other pathological features in vivo.

Authors:  Jin-Woo Kim; Ekaterina I Galanzha; David A Zaharoff; Robert J Griffin; Vladimir P Zharov
Journal:  Mol Pharm       Date:  2013-02-25       Impact factor: 4.939

Review 10.  Circulating tumor cells: advances in isolation and analysis, and challenges for clinical applications.

Authors:  Ramdane Harouaka; Zhigang Kang; Si-Yang Zheng; Liang Cao
Journal:  Pharmacol Ther       Date:  2013-10-14       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.